Streetbeat News

Products Services

AAPL

Apple has announced that its upcoming Apple Watch Series 9 will use 100% recycled cobalt in its battery. This move is part of Apple's commitment to environmental sustainability.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 5:23 pm

CVS

CVS Health Corp has halted the sale of its brand Pink Eye Relief Eye Drops at its stores and online following a warning letter from the FDA.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 5:16 pm

AAPL

Apple has introduced a new feature in its Apple Watch Series 9 that allows users to control the primary button in an app through a double tab gesture.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 5:15 pm

AAPL

Apple has introduced a new feature in its Apple Watch Series 9 that allows users to access health data through Siri. This feature is expected to enhance user experience and could potentially boost sales of the product.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 5:11 pm

AAPL

The upcoming Apple Watch Series 9 will feature the S9 chip set.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 5:10 pm

AAPL

Apple has announced the introduction of the Apple Watch Series 9.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 5:09 pm

AAPL

Apple has announced that it is on track to ship its new product, Apple Vision Pro, early next year.

Portfolio Pulse from Bill Haddad

September 12, 2023 | 5:07 pm

TTWO

Take-Two Interactive Software Inc.'s (NASDAQ:TTWO) upcoming GTA 6 has been the subject of numerous online rumors and leaks, including a claim that the game would have a 750GB file size, a story lasting over 400 hours, and a minimum price of $150. These rumors, however, lack credibility and originate from unsubstantiated sources. It's advised to rely on reputable sources and await official announcements.

Portfolio Pulse from Franca Quarneti

September 12, 2023 | 5:00 pm

MNMD

MindMed (NASDAQ:MNMD) has completed the enrollment and dosing phase of its Phase 2b trial, Study MMED008, which is researching the effectiveness of MM-120 in treating Generalized Anxiety Disorder (GAD). The trial recruited 198 participants across 20 clinical sites. The primary objective of the study is to establish the dose-response correlation among four MM-120 doses compared to a placebo. Top-line results are expected in Q4 2023.

Portfolio Pulse from The Dales Report

September 12, 2023 | 4:59 pm

WMT

Walmart CEO, at the Goldman Sachs Conference, stated that they expect prices to decrease in general merchandise in the short term, but not to the levels seen 2 years ago. He also mentioned the need for new Sam's Club stores in Texas and Florida.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 4:56 pm